Compounds > pristanal
Page last updated: 2024-11-12

pristanal

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pristanal: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID14671060
CHEBI ID49189
SCHEMBL ID2870971
MeSH IDM0279923

Synonyms (16)

Synonym
CHEBI:49189
2,6,10,14-tetramethylpentadecanal
pristanal
LMPR0104010012
SCHEMBL2870971
(2s,6r,10r)-2,6,10,14-tetramethylpentadecanal
(2s)-pristanal
(2r,6r,10r)-2,6,10,14-tetramethylpentadecanal
2spr-al
2(r)-pristanal
(2r)-pristanal
2(s)-pristanal
2rpr-al (2r,6r,10r,14)-tetramethylpentadecanal
DTXSID30883161
105373-75-9
Q15313798
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
2-methyl-branched fatty aldehyde
saturated fatty aldehydeA fatty aldehyde in which there is no carbon-carbon unsaturation.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (9)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Fatty acid metabolism113203
Peroxisomal lipid metabolism2552
Alpha-oxidation of phytanate625
Oxidation of Branched-Chain Fatty Acids1122
Phytanic Acid Peroxisomal Oxidation620
Refsum Disease620
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (60.00)18.2507
2000's2 (40.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.14 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phytanic acid
Phytanic Acid: A 20-carbon branched chain fatty acid. In phytanic acid storage disease (REFSUM DISEASE) this lipid may comprise as much as 30% of the total fatty acids of the plasma. This is due to a phytanic acid alpha-hydroxylase deficiency.. phytanic acid : A branched-chain saturated fatty acid consisting of hexadecanoic acid carrying methyl substituents at positions 3, 7, 11 and 15.		4.250branched-chain saturated fatty acid;
long-chain fatty acid;
methyl-branched fatty acid
coenzyme a
[no description available]		1.9910adenosine 3',5'-bisphosphatecoenzyme;
Escherichia coli metabolite;
mouse metabolite
pristanic acid
pristanic acid : A branched, long-chain saturated fatty acid composed of pentadecanoic acid having methyl substituents at the 2-, 6-, 10- and 14-positions.		2.420branched-chain saturated fatty acid;
long-chain fatty acid;
methyl-branched fatty acid		human metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Congenital Icthyosis Mental Retardation Spasticity Syndrome
[description not available]		02.420
Sjogren-Larsson Syndrome
An autosomal recessive neurocutaneous disorder characterized by severe ichthyosis MENTAL RETARDATION; SPASTIC PARAPLEGIA; and congenital ICHTHYOSIS. It is caused by mutation of gene encoding microsomal fatty ALDEHYDE DEHYDROGENASE leading to defect in fatty alcohol metabolism.		02.420
Adult Refsum Disease
[description not available]		0210